| pubmed-article:18546263 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C2931822 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C1441547 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0205359 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C0178499 | lld:lifeskim |
| pubmed-article:18546263 | lifeskim:mentions | umls-concept:C1626935 | lld:lifeskim |
| pubmed-article:18546263 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18546263 | pubmed:dateCreated | 2008-6-25 | lld:pubmed |
| pubmed-article:18546263 | pubmed:abstractText | Immunotherapy approaches targeting Epstein-Barr virus (EBV)-encoded antigens induce objective clinical responses only in a fraction of patients with undifferentiated nasopharyngeal carcinoma (UNPC). In the present study, we have characterized the immunogenicity of the EBV-encoded BARF1 oncogene with the aim to assess whether this protein could constitute a new target antigen for immunotherapy in this setting. Spontaneous CD4+ and CD8+ T cell responses specific for the recombinant p29 BARF1 protein were detected by IFNgamma-ELISPOT in both EBV-seropositive donors and UNPC patients, but not in EBV-seronegative individuals. Using immunoinformatic prediction tools, we have selected 5 different candidate BARF1 T cell epitopes presented by HLA-A*0201. Although only one of these peptides was able to bind HLA-A2 with low affinity in the T2 stabilization assay, all 5 BARF1 nonamers readily elicited specific CD8+ T cell responses in EBV-seropositive HLA-A*0201+ donors and UNPC patients. Notably, the magnitude of CD8+ T cell responses to the whole BARF1 protein and derived A*0201 peptides was significantly higher in UNPC patients than in healthy donors. Moreover, cytotoxic T lymphocytes specific for the p2-10, p23-31, or p49-57 BARF1 peptides were easily obtained from HLA-A*0201+ donors. These cultures were not only able to lyse autologous targets loaded with the antigenic peptide, but also recognized tumor cells endogenously expressing BARF1 in an antigen-specific and HLA-A2-restricted manner. These findings, indicate that BARF1 is a particularly attractive antigen with immunogenic properties in most UNPC patients and provide valuable information to develop new strategies to improve the efficacy of EBV-targeting immunotherapy of UNPC patients. | lld:pubmed |
| pubmed-article:18546263 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18546263 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18546263 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18546263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18546263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18546263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18546263 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18546263 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18546263 | pubmed:issn | 1097-0215 | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:GloghiniAnnun... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:CarboneAntoni... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:DolcettiRicca... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:De ReValliV | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:VaccherEmanue... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:TedeschiRosa... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:FranchinGiova... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:BarzanLuigiL | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:OokaTadamasaT | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:CaggiariLaura... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:PavanAlessand... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:Da... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:MartorelliDeb... | lld:pubmed |
| pubmed-article:18546263 | pubmed:author | pubmed-author:HoualiKarimK | lld:pubmed |
| pubmed-article:18546263 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18546263 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:18546263 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:18546263 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18546263 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18546263 | pubmed:pagination | 1100-7 | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:meshHeading | pubmed-meshheading:18546263... | lld:pubmed |
| pubmed-article:18546263 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18546263 | pubmed:articleTitle | Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy. | lld:pubmed |
| pubmed-article:18546263 | pubmed:affiliation | Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, PN, Italy. | lld:pubmed |
| pubmed-article:18546263 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18546263 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| lhgdn:association:62968 | lhgdn:found_in | pubmed-article:18546263 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18546263 | lld:pubmed |
